Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile...
Read More Details
Finally We wish PressBee provided you with enough information of ( Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress )
Also on site :
- Winner in Winters: Small-town liquor store sells winning $1M scratcher to "regular customer"
- Justin Bieber's Unsettling Filtered Videos on 'Gucci,' Alaska & Faith Escalate Well-Being Concerns
- Children evacuated from Swindon school after threats of ‘suspicious package’